Navigation Links
Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015
Date:11/10/2010

Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed... -- DALLAS, November 10, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Medical Equipment, Medical Pharmaceuticals, New Products & Services, Surveys, Polls and Research Click to view news release full screen  

Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015

 

DALLAS, November 10, 2010 /PRNewswire/ -- The report analyzes the PET SPECT Market ( http://www.marketsandmarkets.com/Market-Reports/pet-market-98.html) by technologies and applications and studies the major market drivers, restraints, and opportunities for the PET SPECT market in U.S., EMEA, and Asia-Pacific.

Browse market data tables and in-depth TOC on Advanced PET (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) Global Market (2010 -2015)

Early buyers will receive 10% customization of reports. http://www.marketsandmarkets.com/Market-Reports/pet-market-98.html

Propelled by the transparent reimbursement policies, new emerging economies, novel applications such as Alzheimer's and continually expanding oncology application segment, the global positron emission tomography (PET) market is estimated to reach around $6.3 billion in 2010.

Reimbursement plays a major role in the adoption of any medical imaging technology. The approval of PET scanning reimbursement in the U.S. by the Medicare and Medicaid for the Alzheimer's disease widened the opportunities for the major market participants. Currently, there are approximately 4.7 million Alzheimer's patients in the U.S. PET enables the radiologist to have the early diagnosis of the Alzheimer disease among the patients. Therefore, this would further increase the demand of the PET scanners among the various health care centers.

Similarly, single photon emission computed tomography (SPECT) scanners have been on the forefront to bring about significant changes in the diagnostic imaging equipment landscape by opening up numerous lucrative opportunities in niche market such as neuroendocrine tumor imaging. Moreover, technological advancements such as attenuation correction and image acquisition/reconstruction tools have enhanced SPECT end users' confidence in its diagnostic and prognostic capabilities. The global PET SPECT market is expected to grow from an estimated $6.5 billion in 2010 to $10.3 billion in 2015, at an estimated CAGR of 9.4% from 2010 to 2015. The PET segment is estimated to account for the largest share - i.e. 75% - of the overall PET SPECT installations at 3,691 units in 2010. This segment is expected to reach 6,390 units in 2015, at a CAGR of 11.6% for the same period.

The PET/CT segment accounted for the largest share - i.e. 97% - of the overall PET market at an estimated $6.1 billion in 2010. This segment is expected to reach $ 9.8 billion in 2015, at a CAGR of 9.8% for the period 2010 to 2015. Oncology and cardiology are the most significant applications of the PET SPECT market. Oncology accounts for about 90% of the PET market, whereas cardiology accounts for about 85% of SPECT application market. Neurological application of PET and SPECT is a niche market and is dependent on the development of appropriate radionuclides and tracers.

Scope of the report

This research report categorizes the global PET SPECT market on the basis of technology, application, and geography; forecasting revenues and analyzing trends in each of the following submarkets:

- On the basis of technology: - Stand alone PET, PET/CT, stand alone SPECT and SPECT/CT - On the basis of application: - Oncology, non small cell lung cancer, Hodgkin and non Hodgkin lymphoma, head and neck cancer, colorectal cancer, breast cancer; cardiology and neurology - On the basis of geography: - U.S., EMEA (Europe, Middle East and Africa), Asia-Pacific and Rest of the world

About MarketsandMarkets

MarketsandMarkets (M&M) is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services.

M&M covers thirteen industry verticals, including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website http://www.marketsandmarkets.com

Contact: Ms. Sunita 7557 Rambler Road Suite 727, Dallas, TX 75231 Tel: +1-888-989-8004 Email: sales@marketsandmarkets.com http://www.marketsandmarkets.com http://marketsandmarkets.wordpress.com/ http://marketsandmarkets.blogspot.com/
'/>"/>

SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
3. Directors Forum: PEPFAR and the Global AIDS Response
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
7. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
8. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
9. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
10. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
11. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... Clara, CA (PRWEB) , ... April 28, 2017 ... ... is pleased to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep ... user experience, since it streamlines the reporting process and provides a familiar interface ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
Breaking Medicine News(10 mins):